Search

Your search keyword '"Genentech Inc. -- Intellectual property"' showing total 17 results
Start Over Descriptor "Genentech Inc. -- Intellectual property" Publisher comtex news network, inc.
17 results on '"Genentech Inc. -- Intellectual property"'

1. Pertuzumab - Patent, Extension and Data Exclusivity Expiry Snapshot

Subjects
Genentech Inc. -- Intellectual property, Patents, General interest, News, opinion and commentary
Abstract

Sep 14, 2015 (M2 PRESSWIRE via COMTEX) -- Research and Markets (http://www.researchandmarkets.com/research/xgzntk/pertuzumab) has announced the addition of the 'Pertuzumab - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries)' report [...]

Published
2015

2. Galena Biopharma Announces Notice of Allowance of U.S. Patent Application for NeuVax(TM) (nelipepimut-S) Combination

Subjects
Genentech Inc. -- Intellectual property, Biological products industry -- Intellectual property, Biotechnology industry -- Intellectual property, Sulfur compounds, Patents, Patent/copyright issue, Banking, finance and accounting industries, Business, Herceptin (Medication)
Abstract

PORTLAND, Ore., Oct 08, 2014 (GLOBE NEWSWIRE via COMTEX) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major medical needs across [...]

Published
2014

3. Genentech and Biogen Idec Refused a Re-hearing of U.S. Court of Appeals Decision in the Arzerra Patent Infringement Case

Subjects
United States. Court of Appeals for the Federal Circuit, Genentech Inc. -- Intellectual property, Genmab A/S -- Intellectual property, Biological products industry -- Intellectual property, Patent infringement, Pharmaceutical industry -- Intellectual property, Banking, finance and accounting industries, Business, Arzerra (Medication)
Abstract

COPENHAGEN, Denmark, Jul 15, 2013 (GLOBE NEWSWIRE via COMTEX) -- Company Announcement -- Genentech and Biogen Idec refused re-hearing in Arzerra patent infringement case Genmab A/S (Copenhagen:GEN) announced today that [...]

Published
2013

4. Genentech and Biogen Idec Have Filed for a Re-hearing of U.S. Court of Appeals Decision in the Arzerra Patent Infringement Case

Subjects
United States. Court of Appeals for the Federal Circuit, Genentech Inc. -- Intellectual property, Genmab A/S -- Intellectual property, Biological products industry -- Intellectual property, Patent infringement, Pharmaceutical industry -- Intellectual property, Banking, finance and accounting industries, Business, Arzerra (Medication)
Abstract

COPENHAGEN, Denmark, May 17, 2013 (GLOBE NEWSWIRE via COMTEX) -- Company Announcement -- Genentech and Biogen Idec have filed for re-hearing in the United States Genmab A/S (Copenhagen:GEN) announced today [...]

Published
2013

5. Genentech announces new data from CLEOPATRA study showing Perjeta treatment significantly extends life of HER2-positive metastatic breast cancer patents

Subjects
Genentech Inc. -- Intellectual property, Roche Holding AG -- Intellectual property, Biological products industry -- Intellectual property, Oncology, Experimental, Metastasis, Biotechnology industry -- Intellectual property, Cancer -- Care and treatment -- Chemotherapy -- Research, Chemotherapy, Patents, Breast cancer, Pharmaceutical industry -- Intellectual property, Patent/copyright issue, General interest, News, opinion and commentary, Herceptin (Medication) -- Intellectual property
Abstract

Jun 22, 2012 (M2 EQUITYBITES via COMTEX) -- Biotechnology company Genentech, a member of the Roche Group (SIX: RO)(OTCQX: RHHBY), announced today that new data from Phase III CLEOPATRA study [...]

Published
2012

6. Genmab Announces Patent Settlement Agreement for Ofatumumab

Subjects
Genentech Inc. -- Intellectual property, Genmab A/S -- Intellectual property, Biological products, Biotechnology industry -- Intellectual property, Patents, Pharmaceutical industry -- Intellectual property, Patent/copyright issue, Banking, finance and accounting industries, Business
Abstract

Byline: Staff Mar 26, 2012 (GlobeNewswire via COMTEX) -- - GSK enters patent settlement with Genentech regarding ofatumumab - Patents relate to recombinant antibody production - Financial details of settlement [...]

Published
2012

7. Genmab Announces Appeal of US Court Judgment in Favor of Arzerra in Patent Infringement Lawsuit

Subjects
Genentech Inc. -- Intellectual property, Genmab A/S -- Intellectual property, Biological products industry -- Intellectual property, Patent infringement, Pharmaceutical industry -- Intellectual property, Banking, finance and accounting industries, Business, Arzerra (Medication)
Abstract

Byline: Staff COPENHAGEN, Denmark, Dec 6, 2011 (GlobeNewswire via COMTEX) -- Genmab A/S (Copenhagen:GEN) announced today that Genentech and Biogen Idec have appealed the judgment in favor of GlaxoSmithKline (GSK) [...]

Published
2011

8. US court decision on Genmab infringing Genentech, Biogen Idec patent appealed

Subjects
Genentech Inc. -- Intellectual property, Genmab A/S -- Intellectual property, Biogen Idec Inc. -- Intellectual property, Biological products industry -- Intellectual property, Antineoplastic agents, Biotechnology industry -- Intellectual property, Patent infringement, Pharmaceutical industry -- Intellectual property, Antimitotic agents, General interest, News, opinion and commentary, Arzerra (Medication)
Abstract

Dec 06, 2011 (M2 EQUITYBITES via COMTEX) -- 6 December 2011 - Danish biopharma company Genmab A/S (CPH:GEN) announced today the court decision saying that its leukaemia drug Arzerra did [...]

Published
2011

9. US court decision on Genmab infringing Genentech, Biogen Idec patent appealed

Subjects
Genentech Inc. -- Intellectual property, Genmab A/S -- Intellectual property, Biogen Idec Inc. -- Intellectual property, Biological products industry -- Intellectual property, Antineoplastic agents, Biotechnology industry -- Intellectual property, Patent infringement, Pharmaceutical industry -- Intellectual property, Antimitotic agents, General interest, News, opinion and commentary, Arzerra (Medication)
Abstract

Dec 06, 2011 (NORDIC BUSINESS REPORT via COMTEX) -- 6 December 2011 - Danish biopharma company Genmab A/S (CPH:GEN) announced today the court decision saying that its leukaemia drug Arzerra [...]

Published
2011

10. Genmab Announces US Court Judgment in Favor of Arzerra in Patent Infringement Lawsuit

Subjects
Genentech Inc. -- Intellectual property, Genmab A/S -- Intellectual property, Biological products industry -- Intellectual property, Biological products, Patent infringement, Pharmaceutical industry -- Intellectual property, Banking, finance and accounting industries, Business, Arzerra (Medication)
Abstract

Byline: Staff COPENHAGEN, Denmark, Nov 17, 2011 (GlobeNewswire via COMTEX) -- Genmab A/S (Copenhagen:GEN) announced today that a US District Court entered final judgment in favour of GlaxoSmithKline (GSK) in [...]

Published
2011

11. US court rules in favour of Genmab, GSK in Arzerra patent dispute

Subjects
Genentech Inc. -- Intellectual property, Genmab A/S -- Intellectual property, Biogen Idec Inc. -- Intellectual property, Biological products industry -- Intellectual property, Antineoplastic agents, Biotechnology industry -- Intellectual property, Patent infringement, Pharmaceutical industry -- Intellectual property, Antimitotic agents, General interest, News, opinion and commentary, Arzerra (Medication)
Abstract

Nov 17, 2011 (M2 EQUITYBITES via COMTEX) -- 17 November 2011 - Danish biopharma company Genmab A/S (CPH:GEN) said today a US district court decided that its leukaemia drug Arzerra [...]

Published
2011

12. US court rules in favour of Genmab, GSK in Arzerra patent dispute

Subjects
Genentech Inc. -- Intellectual property, Genmab A/S -- Intellectual property, Biogen Idec Inc. -- Intellectual property, Biological products industry -- Intellectual property, Antineoplastic agents, Biotechnology industry -- Intellectual property, Patent infringement, Pharmaceutical industry -- Intellectual property, Antimitotic agents, General interest, News, opinion and commentary, Arzerra (Medication)
Abstract

Nov 17, 2011 (NORDIC BUSINESS REPORT via COMTEX) -- 17 November 2011 - Danish biopharma company Genmab A/S (CPH:GEN) said today a US district court decided that its leukaemia drug [...]

Published
2011

13. Declaratory Relief Complaint for Patent Infringement Under Patent Based on Manufacture, Marketing and Sale of Arzerra

Subjects
Genentech Inc. -- Intellectual property, Genmab A/S -- Intellectual property, Biogen Idec Inc. -- Intellectual property, Biological products industry -- Intellectual property, Pharmaceutical industry -- Intellectual property, Biotechnology industry -- Intellectual property, Patent infringement, Banking, finance and accounting industries, Business
Abstract

Byline: Staff COPENHAGEN, Denmark, Mar 25, 2010 (GlobeNewswire via COMTEX) -- Genmab A/S (Other OTC:GNMSF) (Copenhagen:GEN) announced today that on March 23, 2010 Genentech, Inc. and Biogen Idec, Inc. filed [...]

Published
2010

14. SmallCap Sentinel: The Ever-Increasing Applications for Non-Controversial Adult Stem Cells

Subjects
Genentech Inc. -- Intellectual property, Cell research, Embryonic stem cells, Banking, finance and accounting industries, Business
Abstract

IRVINE, Calif., Aug 7, 2006 (PRIMEZONE via COMTEX) -- 'As the headline-grabbing battle regarding embryonic stem cell research rages, adult stem cell sources continue to provide an ever-broadening array of [...]

Published
2006

15. SmallCap Sentinel: Patent Application Announces Stem Cell Treatment for Back Problems

Subjects
Genentech Inc. -- Intellectual property, Genentech Inc. -- Reports, Stem cells -- Reports, Patents -- Reports, Patent/copyright issue, Banking, finance and accounting industries, Business
Abstract

IRVINE, Calif., May 25, 2006 (PRIMEZONE via COMTEX) -- 'Stem cells continue to make news as new treatments are announced periodically,' stated SmallCap Sentinel analyst D.R. Clark. 'We're seeing enthralling [...]

Published
2006

16. Special Situation Alerts for Monday, March 20, 2006: MXAM - Emerging Growth Situation! NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Market Pulse

Subjects
Genentech Inc. -- Intellectual property, Mineral industry -- Intellectual property, Mining industry -- Intellectual property
Abstract

ATLANTA, GA, Mar 20, 2006 (MARKET WIRE via COMTEX) -- Market Pulse is pleased to introduce our featured stock, Maxam Gold Corporation (OTC: MXAM), to the investment community! Maxam Gold […]

Published
2006

17. SmallCap Sentinel: Patents, Cancer Drugs and Knowing Who Has the Goods

Subjects
Genentech Inc. -- Intellectual property, Market Pathways Financial Relations Inc. -- Intellectual property, Biotechnology industry -- Intellectual property, Cancer -- Care and treatment, Antimitotic agents, Antineoplastic agents, Banking, finance and accounting industries, Business
Abstract

IRVINE, Calif., Dec 1, 2005 (PRIMEZONE via COMTEX) -- 'Recent announcements by biotechnology firms related to the development of new treatments and cures for cancer have stoked interest in biotechnology,' [...]

Published
2005

Catalog

Books, media, physical & digital resources
See catalog results